Our Foundation
Where We've Been.
Dr. Garabedian will give update on researchers by KATHLEEN EDGECOMB A founding member of Terri Brodeur Breast Cancer Foundation’s Scientific Advisory Board will be the keynote speaker at the 13th annual meeting June 18, 2019, in East Lyme. Michael Garabedian, PhD, professor and course director at New York University Medical Center, will talk about the […]
Congratulations to the 2018 top fundraisers By SANDY MANISCALCO There are individuals and groups who have always gone above and beyond and given more than 100 percent in fundraising efforts: they host events, they run promotions, they walk as individuals and they establish walk teams. Over the years, we have acknowledged these heroes at our […]
Big Y and its employees donate to TBBCF to help fight breast cancer Big Y has donated $3,000 to the Terri Brodeur Breast Cancer Foundation as part of its annual Partners of Hope Campaign. On March 9, Big Y store managers at the Stonington location presented a check to TBBCF board member, Patti Burmahl. Every […]
TBBCF funds four grants for breast cancer research By KATHLEEN EDGECOMB The Terri Brodeur Breast Cancer Foundation has awarded $400,000 in research grants to four women who are trying to find a cure for breast cancer and are searching for better ways to treat those who are diagnosed with cancer, “There is an energy and […]
Big Y is spreading TBBCF message In February, Big Y in Groton will donate $1 to the Terri Brodeur Breast Cancer Foundation for every reusable grocery bag it sells at the checkout line. TBBCF has been chosen by the Big Y at 905 Poqunnock Road, as the latest non-profit to benefit from the Community Bag […]
Laura Spring, MD Massachusetts General Hospital Localized breast cancer patients with higher risk disease are often treated with chemotherapy in the neoadjuvant (before surgery) setting. However, it is difficult to predict how breast cancer will respond to treatment given in the neoadjuvant setting and we currently lack any specific blood tests to help answer this […]
Jing Hu, PhD Memorial Sloan Kettering Cancer Center Metastasis is a major clinical hurdle in breast cancer treatment, with poor prognosis (5-year survival around 26.5%). Despite surgical resection of the primary tumor and systemic therapy to suppress residual disease, distant metastatic relapse may still occur within a few months to years, implying the existence of […]
Veerle Daniels, PhD Dana-Farber Cancer Institute Despite recent advances in treatment options, breast cancer remains the second leading cause of cancer-related deaths in women. Triple negative breast cancer (TNBC) is a subgroup of breast cancer that is characterized by the absence of the estrogen receptor, the progesterone receptor and HER2-amplification. Because of the lack of these […]
Ana Garrido-Castro, MD Dana-Farber Cancer Institute Choosing the best treatments for metastatic breast cancer depends increasingly on molecular features, such as tumor subtype. Patients with hormone receptor-positive/HER2-negative breast cancer are typically treated initially with hormonal therapies, and then subsequently with chemotherapy once hormonal therapy loses its effectiveness. Loss of hormone receptor expression has been described as a […]
College student is link between researchers and scientific advisory board By KATHLEEN EDGECOMB Gabby Gualtieri was 10 or 11 when she first became involved with the Terri Brodeur Breast Cancer Foundation. She remembers handing out drinks, snacks and candy with her family to participants during the annual Walk Across Southeastern Connecticut fundraiser. “The marathon was […]
our sponsors
Platinum & Diamond Partners
